VANGUARD GROUP INC 13D and 13G filings for Esperion Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 2:23 pm Unchanged | 2024-09-30 | 13G | Esperion Therapeutics, Inc. ESPR | VANGUARD GROUP INC | 13,043,077 6.640% | 0 (Unchanged) | Filing |
| 2024-11-04 1:33 pm Unchanged | 2024-09-30 | 13G | Esperion Therapeutics, Inc. ESPR | VANGUARD GROUP INC | 13,043,077 6.640% | 0 (Unchanged) | Filing |
| 2024-11-04 12:09 pm Purchase | 2024-09-30 | 13G | Esperion Therapeutics, Inc. ESPR | VANGUARD GROUP INC | 13,043,077 6.640% | 7,905,327 (+153.87%) | Filing |
| 2024-02-13 5:04 pm Purchase | 2023-12-29 | 13G | Esperion Therapeutics, Inc. ESPR | VANGUARD GROUP INC | 5,137,750 4.520% | 877,286 (+20.59%) | Filing |
| 2023-02-09 11:19 am Purchase | 2022-12-30 | 13G | Esperion Therapeutics, Inc. ESPR | VANGUARD GROUP INC | 4,260,464 5.780% | 499,025 (+13.27%) | Filing |
| 2022-02-10 08:11 am Purchase | 2021-12-31 | 13G | Esperion Therapeutics, Inc. ESPR | VANGUARD GROUP INC | 3,761,439 6.060% | 1,396,132 (+59.03%) | Filing |
| 2021-02-10 10:52 am Sale | 2020-12-31 | 13G | Esperion Therapeutics, Inc. ESPR | VANGUARD GROUP INC | 2,365,307 8.480% | -282,604 (-10.67%) | Filing |